Development of a vaccine against Staphylococcus aureus based on novel targets

基于新靶点开发金黄色葡萄球菌疫苗

• 批准号: G1000768/1
• 负责人: Simon J. Foster
• 金额: $ 30.53万
• 依托单位: University of Sheffield
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1000768%2F1
• 关键词: Development; vaccine; against; Staphylococcus; aureus

Infectious disease is still a major killer around the world. The rise of hospital acquired infections and the antibiotic resistant superbugs are a constant threat to the UK healthcare system. Foremost amongst the superbugs is MRSA (Methicillin Resistant Staphylococcus aureus). MRSA is an antibiotic resistant variant of S. aureus. All S. aureus strain, including MRSA, can live in the noses of humans and this forms an ideal reservoir from which to infect patients. It also makes it very difficult to eradicate these organisms form the human environment. To address the ongoing healthcare problem, novel strategies including antibiotics and a vaccine and are needed. At present there is no vaccine against MRSA and other S. aureus strains available. The main patient groups for vaccination would be those on dialysis, elective surgery patients and diabetics. Others could include residents of long term care/nursing homes. An effective vaccine would have significant impact in reducing both disease burden and outcome, with associated reduction in human and financial costs. The aim of the proposed project is to produce the first vaccine against MRSA and other Staphylococcus aureus strains. We have identified and filed patents on novel S. aureus vaccine components. The components are made by all strains and are required for the ability of the organism to cause disease and/or grow. Thus the organism cannot do without them. Most importantly, we have shown that experimental vaccination with these components can protect against S. aureus infection. The key goal of the project is to develop the best formulation of our components to take forward to the clinic. The aim is to test combinations of the components and other parameters to select the most effective formulation to progress into pre-clinical safety evaluation and human clinical trials.

传染病仍然是世界各地的主要杀手。医院收到感染和抗生素耐药超级细菌的兴起对英国医疗保健系统持续威胁。超级细菌中最重要的是MRSA（甲氧西林金黄色葡萄球菌）。 MRSA是金黄色葡萄球菌的一种抗生素抗性变体。包括MRSA在内的所有金黄色葡萄球菌菌株都可以生活在人类的鼻子中，这形成了一种理想的储层，从中可以感染患者。这也使根除这些生物形成人类环境非常困难。为了解决正在进行的医疗保健问题，需要新的策略，包括抗生素和疫苗，需要。目前，没有针对MRSA和其他金黄色葡萄球菌菌株的疫苗。疫苗接种的主要患者组是透析，选修手术患者和糖尿病患者。其他人可能包括长期护理/疗养院的居民。有效的疫苗将对减轻疾病负担和结果产生重大影响，并减少人类和财务成本。拟议项目的目的是生产第一种针对MRSA和其他金黄色葡萄球菌菌株的疫苗。我们已经在新型金黄色葡萄球菌疫苗成分上确定并申请了专利。组件是由所有菌株制成的，是生物体引起疾病和/或生长的能力所必需的。因此，没有它们就无法做到。最重要的是，我们已经表明，使用这些成分的实验疫苗可以预防金黄色葡萄球菌感染。该项目的关键目标是开发我们组件的最佳配方，以送往诊所。目的是测试组件和其他参数的组合，以选择最有效的配方，以发展为临床前安全评估和人类临床试验。